Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders

Merck is mulling whether to file its CETP medication anacetrapib after posting some surprising positive topline data from the Reveal test.

RNA interference (RNAi) specialist Alnylam has hit the accelerator on its candidate drug for ultrarare porphyria diseases.

Neothetics said its phase 2 proof-of-concept study for its fat reduction therapy has flopped.

Roche has released a closer look at the data it hopes will propel hemophilia A drug emicizumab to blockbuster status.

Matinas BioPharma was off by nearly 50% on data coming out of its midstage vulvovaginal candidiasis candidate.

Kala Pharmaceuticals has filed to list on Nasdaq to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications.

Bluebird Bio reported encouraging data on revamped gene therapy for sickle cell disease and beta thalassemia, but shares slipped 6% premarket.

GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.

Aveo Pharmaceuticals’ troubled tivozanib is on the cusp of winning approval in Europe, sending its stock on a tear.